Jefferies analyst Farzin Haque initiated coverage of Vor Bio (VOR) with a Buy rating and $50 price target which represents 268% upside. The company pivoted to autoimmune diseases in June of 2025 by licensing telitacicept globally outside of China from RemeGen, the analyst tells investors in a research note. The firm believes telitacicept is “well validated” in China. Jefferies sees a “valuation disconnect” in Vor shares and expects “outsized moves” with the pivotal generalized myasthenia gravis data in the first half of 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating
- Vor Biopharma Announces $75 Million Private Placement Financing
- Vor Bio to sell 5.338M shares at $14.05 in private placement
- Vor Bio initiated with an Overweight at Wells Fargo
- VOR Earnings this Week: How Will it Perform?